ACRS · CIK 0001557746 · operating
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing drug candidates for immune-inflammatory diseases. The company's therapeutic pipeline includes ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b development for atopic dermatitis; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trials for moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 in Phase 2a for T cell-mediated autoimmune diseases; and Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor in Phase 1b/2 trials for metastatic breast cancer and pancreatic ductal adenocarcinoma. Additional candidates include ATI-052, a bispecific antibody in preclinical stage, and an ITK selective inhibitor for autoimmune diseases.
The company operates two segments: Therapeutics, which encompasses drug development efforts, and Contract Research, which provides laboratory services. Aclaris is headquartered in Wayne, Pennsylvania, with approximately 61 full-time employees. The company was incorporated in Delaware in 2012 and is listed on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-0.53 | $-0.53 | +69.0% | |
| 2024 | $-1.71 | $-1.71 | -34.6% | |
| 2023 | $-1.27 | $-1.27 | +4.5% | |
| 2022 | $-1.33 | $-1.33 | +16.9% | |
| 2021 | $-1.60 | $-1.60 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-26 | 0001104659-26-020540 | SEC ↗ |
| 2024-12-31 | 2025-02-27 | 0001558370-25-001819 | SEC ↗ |
| 2023-12-31 | 2024-02-27 | 0001558370-24-001753 | SEC ↗ |
| 2022-12-31 | 2023-02-23 | 0001558370-23-001829 | SEC ↗ |
| 2021-12-31 | 2022-02-24 | 0001558370-22-001838 | SEC ↗ |
| 2020-12-31 | 2021-02-25 | 0001558370-21-001717 | SEC ↗ |
| 2019-12-31 | 2020-02-25 | 0001558370-20-001325 | SEC ↗ |
| 2018-12-31 | 2019-03-18 | 0001558370-19-002211 | SEC ↗ |
| 2017-12-31 | 2018-03-12 | 0001558370-18-001866 | SEC ↗ |
| 2016-12-31 | 2017-03-15 | 0001558370-17-001802 | SEC ↗ |
| 2015-12-31 | 2016-03-23 | 0001558370-16-004311 | SEC ↗ |